Extracellular Vesicles from miR-146a Overexpressing Mesenchymal Stem Cells Attenuate ‎Imiquimod-Induced Psoriasis by Regulating Cytokine Expression

Psoriasis is a chronic inflammatory skin disorder characterized by elevated levels of proinflammatory cytokines. Mesenchymal stem cells (MSCs) have demonstrated therapeutic potential, yet the specific mechanisms involved are not fully understood. To investigated the effectiveness of extracellular ve...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Iranian journal of immunology Ročník 22; číslo 2; s. 119
Hlavní autoři: Shao, Hongmei, Chen, Junjie
Médium: Journal Article
Jazyk:angličtina
Vydáno: Iran Shiraz Institute for Cancer Research 23.06.2025
Témata:
ISSN:1735-1383, 1735-367X, 1735-367X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Psoriasis is a chronic inflammatory skin disorder characterized by elevated levels of proinflammatory cytokines. Mesenchymal stem cells (MSCs) have demonstrated therapeutic potential, yet the specific mechanisms involved are not fully understood. To investigated the effectiveness of extracellular vesicles (EVs) derived from MSCs that were genetically modified to overexpress miR-146a, in a mouse model of psoriasis. To enhance miR-146a expression, MSCs were transfected, and their EVs were subsequently purified. Thirty mice were randomly assigned to three groups and induced with imiquimod cream to develop psoriasis-like skin lesions. The treatment groups included: (1) a control group administered PBS, (2) a group treated with EVs containing a control miRNA (miR-control EVs), and (3) a group receiving EVs enriched with miR-146a (miR-146a-EVs). EVs were administered intravenously and lesions were evaluated. Following intravenous administration of EVs, the severity of skin lesions was assessed. Concentrations of key cytokines, including IFN-γ, IL-17, TNF-α, IL-23, IL-6, IL-1β, TGF-β, IL-10, and IL-4, were quantified in both spleen and skin tissue lysates using ELISA and qRT-PCR techniques. The experimental findings demonstrated that the administration of miR-146a-enriched EVs led to a significant improvement in clinical symptoms. There were substantial reductions observed in combined erythema, scaling, and skin thickness measurements compared to untreated controls. Additionally, levels of proinflammatory cytokines IFN-γ, IL-17, TNF-α, IL-23, IL-6, and IL-1β were significantly downregulated in the miR-146a-EV group, while anti-inflammatory TGF-β, IL-10 and IL-4 were upregulated. The same results were obtained in the spleens of mice. EVs derived from miR-146a-modified MSCs effectively reduced psoriasis-like inflammation by modulating cytokine expression. This novel cell-free therapy holds promise for the treatment of psoriasis.
AbstractList Psoriasis is a chronic inflammatory skin disorder characterized by elevated levels of proinflammatory cytokines. Mesenchymal stem cells (MSCs) have demonstrated therapeutic potential, yet the specific mechanisms involved are not fully understood. To investigated the effectiveness of extracellular vesicles (EVs) derived from MSCs that were genetically modified to overexpress miR-146a, in a mouse model of psoriasis. To enhance miR-146a expression, MSCs were transfected, and their EVs were subsequently purified. Thirty mice were randomly assigned to three groups and induced with imiquimod cream to develop psoriasis-like skin lesions. The treatment groups included: (1) a control group administered PBS, (2) a group treated with EVs containing a control miRNA (miR-control EVs), and (3) a group receiving EVs enriched with miR-146a (miR-146a-EVs). EVs were administered intravenously and lesions were evaluated. Following intravenous administration of EVs, the severity of skin lesions was assessed. Concentrations of key cytokines, including IFN-γ, IL-17, TNF-α, IL-23, IL-6, IL-1β, TGF-β, IL-10, and IL-4, were quantified in both spleen and skin tissue lysates using ELISA and qRT-PCR techniques. The experimental findings demonstrated that the administration of miR-146a-enriched EVs led to a significant improvement in clinical symptoms. There were substantial reductions observed in combined erythema, scaling, and skin thickness measurements compared to untreated controls. Additionally, levels of proinflammatory cytokines IFN-γ, IL-17, TNF-α, IL-23, IL-6, and IL-1β were significantly downregulated in the miR-146a-EV group, while anti-inflammatory TGF-β, IL-10 and IL-4 were upregulated. The same results were obtained in the spleens of mice. EVs derived from miR-146a-modified MSCs effectively reduced psoriasis-like inflammation by modulating cytokine expression. This novel cell-free therapy holds promise for the treatment of psoriasis.
Psoriasis is a chronic inflammatory skin disorder characterized by elevated levels of proinflammatory cytokines. Mesenchymal stem cells (MSCs) have demonstrated therapeutic potential, yet the specific mechanisms involved are not fully understood.BackgroundPsoriasis is a chronic inflammatory skin disorder characterized by elevated levels of proinflammatory cytokines. Mesenchymal stem cells (MSCs) have demonstrated therapeutic potential, yet the specific mechanisms involved are not fully understood.To investigated the effectiveness of extracellular vesicles (EVs) derived from MSCs that were genetically modified to overexpress miR-146a, in a mouse model of psoriasis.ObjectiveTo investigated the effectiveness of extracellular vesicles (EVs) derived from MSCs that were genetically modified to overexpress miR-146a, in a mouse model of psoriasis.To enhance miR-146a expression, MSCs were transfected, and their EVs were subsequently purified. Thirty mice were randomly assigned to three groups and induced with imiquimod cream to develop psoriasis-like skin lesions. The treatment groups included: (1) a control group administered PBS, (2) a group treated with EVs containing a control miRNA (miR-control EVs), and (3) a group receiving EVs enriched with miR-146a (miR-146a-EVs). EVs were administered intravenously and lesions were evaluated. Following intravenous administration of EVs, the severity of skin lesions was assessed. Concentrations of key cytokines, including IFN-γ, IL-17, TNF-α, IL-23, IL-6, IL-1β, TGF-β, IL-10, and IL-4, were quantified in both spleen and skin tissue lysates using ELISA and qRT-PCR techniques.MethodsTo enhance miR-146a expression, MSCs were transfected, and their EVs were subsequently purified. Thirty mice were randomly assigned to three groups and induced with imiquimod cream to develop psoriasis-like skin lesions. The treatment groups included: (1) a control group administered PBS, (2) a group treated with EVs containing a control miRNA (miR-control EVs), and (3) a group receiving EVs enriched with miR-146a (miR-146a-EVs). EVs were administered intravenously and lesions were evaluated. Following intravenous administration of EVs, the severity of skin lesions was assessed. Concentrations of key cytokines, including IFN-γ, IL-17, TNF-α, IL-23, IL-6, IL-1β, TGF-β, IL-10, and IL-4, were quantified in both spleen and skin tissue lysates using ELISA and qRT-PCR techniques.The experimental findings demonstrated that the administration of miR-146a-enriched EVs led to a significant improvement in clinical symptoms. There were substantial reductions observed in combined erythema, scaling, and skin thickness measurements compared to untreated controls. Additionally, levels of proinflammatory cytokines IFN-γ, IL-17, TNF-α, IL-23, IL-6, and IL-1β were significantly downregulated in the miR-146a-EV group, while anti-inflammatory TGF-β, IL-10 and IL-4 were upregulated. The same results were obtained in the spleens of mice.ResultsThe experimental findings demonstrated that the administration of miR-146a-enriched EVs led to a significant improvement in clinical symptoms. There were substantial reductions observed in combined erythema, scaling, and skin thickness measurements compared to untreated controls. Additionally, levels of proinflammatory cytokines IFN-γ, IL-17, TNF-α, IL-23, IL-6, and IL-1β were significantly downregulated in the miR-146a-EV group, while anti-inflammatory TGF-β, IL-10 and IL-4 were upregulated. The same results were obtained in the spleens of mice.EVs derived from miR-146a-modified MSCs effectively reduced psoriasis-like inflammation by modulating cytokine expression. This novel cell-free therapy holds promise for the treatment of psoriasis.ConclusionEVs derived from miR-146a-modified MSCs effectively reduced psoriasis-like inflammation by modulating cytokine expression. This novel cell-free therapy holds promise for the treatment of psoriasis.
Background: Psoriasis is a chronic inflammatory skin disorder characterized by elevated levels of proinflammatory cytokines. Mesenchymal stem cells (MSCs) have demonstrated therapeutic potential, yet the specific mechanisms involved are not fully understood. In this study, we investigated the effectiveness of extracellular vesicles (EVs) derived from MSCs that were genetically modified to overexpress miR-146a, in a mouse model of psoriasis. Methods: To enhance miR-146a expression, MSCs were transfected, and their EVs were subsequently purified. Thirty mice were randomly assigned to three groups and induced with imiquimod cream to develop psoriasis-like skin lesions. The treatment groups included: (1) a control group administered PBS, (2) a group treated with EVs containing a control miRNA (miR-control EVs), and (3) a group receiving EVs enriched with miR-146a (miR-146a-EVs). EVs were administered intravenously and lesions were evaluated. Following intravenous administration of EVs, the severity of skin lesions was assessed. Concentrations of key cytokines, including IFN-γ, IL-17, TNF-α, IL-23, IL-6, IL-1β, TGF-β, IL-10, and IL-4, were quantified in both spleen and skin tissue lysates using ELISA and qRT-PCR techniques. Results: The experimental findings demonstrated that the administration of miR-146a-enriched EVs led to a significant improvement in clinical symptoms. There were substantial reductions observed in combined erythema, scaling, and skin thickness measurements compared to untreated controls. Additionally, levels of proinflammatory cytokines IFN-γ, IL-17, TNF-α, IL-23, IL-6, and IL-1β were significantly downregulated in the miR-146a-EV group, while anti-inflammatory TGF-β, IL-10 and IL-4 were upregulated. The same results were obtained in the spleens of mice. Conclusion: EVs derived from miR-146a-modified MSCs effectively reduced psoriasis-like inflammation by modulating cytokine expression. This novel cell-free therapy holds promise for the treatment of psoriasis.
Author Shao, Hongmei
Chen, Junjie
Author_xml – sequence: 1
  givenname: Hongmei
  orcidid: 0009-0000-1756-1160
  surname: Shao
  fullname: Shao, Hongmei
  organization: Department of Dermatology, Affiliated Hospital of Nantong University, Nantong 226000, Jiangsu Province, China
– sequence: 2
  givenname: Junjie
  orcidid: 0009-0000-7342-4283
  surname: Chen
  fullname: Chen, Junjie
  organization: Department of Anesthesiology, Affiliated Hospital of Nantong University, Nantong 226000, Jiangsu Province, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40546034$$D View this record in MEDLINE/PubMed
BookMark eNpdkM1OGzEUha0KVP76CFSWuulmUv_PzBJFoUSiCoIIdRd5PHfA6dgOtqciuz4BO16QJ-lETTes7l1895x7zgk68MEDQueUTBgjXHyzazthhMkJJUKWasJqUn9Ax7TksuCq_Hmw3ymv-BE6SWlNiFKEko_oSBAp1ChyjF5nzzlqA30_9Drie0jW9JBwF4PDzt4WVCiNF78hwvMmQkrWP-AfkMCbx63TPb7L4PB0vE_4Imfwg86A3_68zJ19GqwLbTH37WCgxTcpRKuTTbjZ4lt4GA3zTm26zeGX9YBne4fgz9Bhp_sEn_bzFC0vZ8vpVXG9-D6fXlwXGyZoLnTdEamFELKSY3reCK0rKSogirYlq5uSU1GWpm7qqjHEVJJ2nQRDWiMkZfwUff0nu4nhaYCUV86mXRfaQxjSijPGuRr74yP65R26DkP043M7SikppCxH6vOeGhoH7WoTrdNxu_rfN_8LMoOHpQ
ContentType Journal Article
Copyright Copyright Shiraz Institute for Cancer Research 2025
Copyright_xml – notice: Copyright Shiraz Institute for Cancer Research 2025
DBID NPM
3V.
7T5
7U9
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
CWDGH
DWQXO
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7N
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
DOI 10.22034/iji.2025.104576.2909
DatabaseName PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Virology and AIDS Abstracts
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest SciTech Premium Collection Natural Science Collection Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
Middle East & Africa Database
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Collection (ProQuest)
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Health & Medical Collection (Alumni Edition)
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle PubMed
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Middle East & Africa Database
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
ProQuest Central Student
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1735-367X
ExternalDocumentID 40546034
Genre Journal Article
GroupedDBID ---
53G
5GY
7X7
88E
8FE
8FH
8FI
8FJ
8R4
8R5
ABUWG
ACPRK
ADBBV
AENEX
AFKRA
AFRAH
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
CWDGH
DIK
EBD
EMOBN
EOJEC
F5P
FRP
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
LK8
M1P
M7P
NPM
OBODZ
OK1
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
RNS
SV3
UKHRP
W2D
3V.
7T5
7U9
7XB
8FK
AFFHD
AZQEC
DWQXO
GNUQQ
H94
K9.
M7N
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
PUEGO
ID FETCH-LOGICAL-p241t-a9f05a4445859093b4aa8548e061d729b731477c9b98bc0c851ff5ec0dc45123
IEDL.DBID M7P
ISICitedReferencesCount 1
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001524814900003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1735-1383
1735-367X
IngestDate Fri Sep 05 15:49:10 EDT 2025
Sat Nov 01 15:03:20 EDT 2025
Tue Jul 01 05:31:17 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Mesenchymal stem cell
Psoriasis
Extracellular vesicle
Exosome
Cytokine
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-p241t-a9f05a4445859093b4aa8548e061d729b731477c9b98bc0c851ff5ec0dc45123
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0009-0000-1756-1160
0009-0000-7342-4283
PMID 40546034
PQID 3226654557
PQPubID 105770
ParticipantIDs proquest_miscellaneous_3223363833
proquest_journals_3226654557
pubmed_primary_40546034
PublicationCentury 2000
PublicationDate 2025-06-23
PublicationDateYYYYMMDD 2025-06-23
PublicationDate_xml – month: 06
  year: 2025
  text: 2025-06-23
  day: 23
PublicationDecade 2020
PublicationPlace Iran
PublicationPlace_xml – name: Iran
– name: Shiraz
PublicationTitle Iranian journal of immunology
PublicationTitleAlternate Iran J Immunol
PublicationYear 2025
Publisher Shiraz Institute for Cancer Research
Publisher_xml – name: Shiraz Institute for Cancer Research
SSID ssj0066010
Score 2.3335602
Snippet Psoriasis is a chronic inflammatory skin disorder characterized by elevated levels of proinflammatory cytokines. Mesenchymal stem cells (MSCs) have...
Background: Psoriasis is a chronic inflammatory skin disorder characterized by elevated levels of proinflammatory cytokines. Mesenchymal stem cells (MSCs) have...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 119
SubjectTerms Cytokines
Erythema
Extracellular vesicles
IL-1β
Imiquimod
Interleukin 10
Interleukin 17
Interleukin 23
Interleukin 4
Interleukin 6
Intravenous administration
Lysates
Mesenchymal stem cells
miRNA
Psoriasis
Skin diseases
Skin lesions
Stem cells
Transforming growth factor-b
Tumor necrosis factor-α
γ-Interferon
Title Extracellular Vesicles from miR-146a Overexpressing Mesenchymal Stem Cells Attenuate ‎Imiquimod-Induced Psoriasis by Regulating Cytokine Expression
URI https://www.ncbi.nlm.nih.gov/pubmed/40546034
https://www.proquest.com/docview/3226654557
https://www.proquest.com/docview/3223363833
Volume 22
WOSCitedRecordID wos001524814900003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 1735-367X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0066010
  issn: 1735-1383
  databaseCode: M7P
  dateStart: 20080301
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1735-367X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0066010
  issn: 1735-1383
  databaseCode: 7X7
  dateStart: 20080301
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Middle East & Africa Database
  customDbUrl:
  eissn: 1735-367X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0066010
  issn: 1735-1383
  databaseCode: CWDGH
  dateStart: 20080301
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/middleeastafrica
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1735-367X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0066010
  issn: 1735-1383
  databaseCode: BENPR
  dateStart: 20080301
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NjtMwELbYXZD2wj9sYamMxNVs6p86PqGl6gokKFVZod4q23F2A2rSbVK0vfEE3HhBnoQZJ4XbXrjkktixxuPxN_bMfIS8EtIazdOM-YHKsah2YC5VloEnFoRDZlgXS-Z_0JNJOp-baXfgVndhlTubGA11Vnk8Iz8BxUOiXKX0m9UVQ9YovF3tKDT2yAFWSRAxdG-6s8RDdDZiQqRQWGtPtBk8nCdCnhRfC_AOucJLTsDcr7lJbkCZcbc5u_e_47xP7nY4k562ivGA3ArlQ3KnZZ7cPiK_xtfN2uKpPYah0i-hjuFxFLNN6LKYMTBtln4CPQ_XbahseUE_YqaSv9wuoePPTVjSEbSv6WkDuHsDmJX-_vHz_bK42sD8ZwxJQXzI6LSG4dm6qKnb0lm4iHxh0Nto21TfAOPScfeHqnxMzs_G56N3rGNoYCvY-RtmTZ4oK6UEpwPkB5NrbQo-UACUkAFsd1oMpNbeOJM6n3iAd3mugk8yD2rAxROyX1ZlOCJU6DDkLpGwZyspdW6MdFyYkA_yoZEy65HjnbgX3SqrF_9k3SMv_76G9YHis2WoNvEbIcDICNEjT9spXazaQh4LAKtyCMrw7ObOn5ND1BQMEOPimOw36014QW77701Rr_tkT891fKZ9cvB2PJnO-lEN_wAdz-Q_
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NctMwENaUFgYu_FMCLYgZ4GbqSPKPDj100pRkmoZOydDePJIst4aJncYO1Lc-ATceg5fiSbprO3DrrQfOtiWN9Gn1rbW7HyFvuVAyYGHsmK6XYFFt6-jQUw54YpZrVIbVdcn8UTAehycn8nCF_F7mwmBY5dIm1oY6zg3-I98C4KFQrucFbQTlvq1-gH9WbA93YTHfMbbXn_QGTish4MzgaCodJRPXU0IIYMUSnHctlAqBpFs4xmLglTrgXREERmoZauMa4B9J4lnjxgbGiUUN2PvZuYMiVXiZ2yp23CJroS9D2FBrvePdj4Ol6ffRu6kzMLmHxf14kzLEmMvFVvo1BXeUeXirCiT_A5PuNbS2Pt72HvxnE_OQ3G95NN1pgP-IrNjsMbnTKGtWT8iv_kU5V3grgWG29Ist6vA_itk0dJoeOWC6Ff0E-9heNKHA2Sk9wEwsc1ZNoeHPpZ3SHnxf0J0S_IoFcHL65_LncJqeLwDfsYOiJ8bG9LCA4akiLaiu6JE9rfXQoLVeVebfgMPTfttDnj0lk5uYpWdkNcsz-5xQHlifaVcAJ_GECBIphWZc2qSb-FKIuEM2lqsbtVakiP4tbYe8-fsY9j9On8psvqjf4RyMKOcdst4gKJo1hUoiIOPCB-y9uL7x1-TuYHIwikbD8f5Lcg9BisFwjG-Q1XK-sJvktvlepsX8VYt3SqIbxtYV6jo8Jw
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELaqLSAuvAsLBYwEx9Cs7Tx8QKjaB121LKtSQW-R7ThtijbZbrLQ3PgF3Pgx_B1-CTN5wK23HjgncRT788w38cx8hLzkQsmAhbFjBl6CTbWto0NPORCJWa5RGVbXLfMPgtksPD6W8w3yq6uFwbTKzibWhjrODf4j3wHgoVCuBwF80qZFzEeTt8tzBxWk8KS1k9NoILJvq28QvhVvpiNY61eMTcZHwz2nVRhwluC5SkfJxPWUEAJIs4TYXgulQuDwFrxcDLRTB3wggsBILUNtXAP0JEk8a9zYwGdgzwOw_puhH3CvRzaHn0fv9jo34GOkU1djcg8b_fGmfIgxl4ud9CyF0JR5eMIKhP81k-4lFLd2dZPb__Ek3SG3Wn5Nd5sNcZds2Oweud4oblb3yc_xRblSeFqB6bf0ky3qtECKVTZ0kR46YNIV_QD72140KcLZCX2PFVrmtFrAwB9Lu6BDeL6guyXEG2vg6vT39x_TRXq-BtzHDoqhGBvTeQGzoYq0oLqih_ak1kmD0YZVmX8Bbk_H7Rvy7AE5uoop2SK9LM_sI0J5YH2mXQFcxRMiSKQUmnFpk0HiSyHiPtnuVjpqrUsR_VvmPnnx9zLYBZw-ldl8Xd_DORhXzvvkYYOmaNk0MImApAsfcPj48sGfkxuAnuhgOtt_Qm4iXjFHjvFt0itXa_uUXDNfy7RYPWuhT0l0xTj6A1oqRN0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Extracellular+Vesicles+from+miR-146a+Overexpressing+Mesenchymal+Stem+Cells+Attenuate+%E2%80%8EImiquimod-Induced+Psoriasis+by+Regulating+Cytokine+Expression&rft.jtitle=Iranian+journal+of+immunology&rft.au=Shao%2C+Hongmei&rft.au=Chen%2C+Junjie&rft.date=2025-06-23&rft.pub=Shiraz+Institute+for+Cancer+Research&rft.issn=1735-1383&rft.eissn=1735-367X&rft.volume=22&rft.issue=2&rft.spage=119&rft_id=info:doi/10.22034%2Fiji.2025.104576.2909&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1735-1383&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1735-1383&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1735-1383&client=summon